Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$9 Mln
Net Profit (TTM)
$0 Mln
ROE
-4.5 %
ROCE
-- %
P/E Ratio
0
P/B Ratio
0.6
Industry P/E
--
EV/EBITDA
-0.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.5
Face value
--
Shares outstanding
5,816,200
CFO
$-90.40 Mln
EBITDA
$-100.48 Mln
Net Profit
$-115.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NovaBay Pharmaceuticals (NBY)
| -5.7 | -5.5 | -10.0 | -87.7 | -86.8 | -77.8 | -65.1 |
|
BSE Sensex
| 3.5 | 1.9 | 7.5 | 9.5 | 14.2 | 21.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
NovaBay Pharmaceuticals (NBY)
| -91.2 | -89.7 | -85.3 | -45.5 | 8.9 | -17.2 | -79.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NovaBay Pharmaceuticals (NBY)
|
0.6 | 3.4 | 9.5 | 3.7 | -36.1 | 101.1 | 0 | 0.6 |
| 47.3 | 7,725.5 | 1,208.8 | 131.7 | 13.4 | 6.3 | 59.4 | 3.8 | |
| 100.3 | 6,652.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 19.4 | |
| 135.6 | 7,049.6 | 4,022.6 | -31.6 | 3.7 | -1.1 | 618.4 | 2.2 | |
| 56.5 | 10,905.2 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.5 | |
| 42.9 | 12,097.3 | 2,298.9 | 643.6 | 27.3 | 29.2 | 20.3 | 5.7 | |
| 53.8 | 6,586.2 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.2 | 13.6 | |
| 293.0 | 8,785.2 | 2,156.6 | 416.4 | 15.6 | 56.5 | 23.3 | 14.8 | |
| 26.7 | 10,824.9 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 119.1 | 12,168.8 | 2,412.6 | 305.8 | 20.5 | 11.6 | 41.7 | 4.8 |
NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly... known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Address: 2000 Powell Street, Emeryville, CA, United States, 94608 Read more
President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director
Mr. Justin M. Hall Esq.
Controller, Interim CFO & Treasurer
Mr. Tommy Law
Headquarters
Emeryville, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of NovaBay Pharmaceuticals Inc (NBY) stood at $ 19 Mln as on 31-Mar-25
The share price of NovaBay Pharmaceuticals Inc (NBY) is $0.57 (NYSE) as of 22-May-2025 16:10 EDT. NovaBay Pharmaceuticals Inc (NBY) has given a return of -86.75% in the last 3 years.
NovaBay Pharmaceuticals Inc (NBY) has a market capitalisation of $ 3 Mln as on 21-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of NovaBay Pharmaceuticals Inc (NBY) is 0.56 times as on 21-May-2025, a 76% discount to its peers’ median range of 2.34 times.
The P/E ratio of NovaBay Pharmaceuticals Inc (NBY) is 0.02 times as on 21-May-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the NovaBay Pharmaceuticals Inc (NBY) and enter the required number of quantities and click on buy to purchase the shares of NovaBay Pharmaceuticals Inc (NBY).
NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Address: 2000 Powell Street, Emeryville, CA, United States, 94608
The CEO & director of Mr. Justin M. Hall Esq.. is NovaBay Pharmaceuticals Inc (NBY), and CFO & Sr. VP is Mr. Tommy Law.
There is no promoter pledging in NovaBay Pharmaceuticals Inc (NBY).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,230
|
|
|
1,176
|
|
|
1,035
|
|
|
929
|
|
|
838
|
|
|
820
|
|
|
750
|
|
|
682
|
|
|
630
|
| NovaBay Pharmaceuticals Inc. (NBY) | Ratios |
|---|---|
|
Return on equity(%)
|
101.15
|
|
Operating margin(%)
|
-36.12
|
|
Net Margin(%)
|
38.7
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of NovaBay Pharmaceuticals Inc (NBY) was $0 Mln.
$0.01
(
